Christina L. Roark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christina L. Roark has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Brian M. Freed
Division of Allergy and Clinical Immunology, School of Medicine, University of Colorado Denver, 13001 E 17th Pl, Aurora, CO, 80045, USA
5 shared publications - Kirsten M. Anderson
Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco , San Francisco, CA 94158
5 shared publications - Michael T. Aubrey
ClinImmune Labs, 12705 E. Montview Blvd, Suite 250, Aurora, CO 80045, USA
4 shared publications Brian M. Freed
University of Colorado, Anschutz Medical Campus Aurora Colorado
3 shared publications- Edward F. Rosloniec
Veterans Affairs Medical Center Memphis Tennessee
3 shared publications Asad Bashey
The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia
2 shared publications
Latest Publications
- 1 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11) , e70514
Excellent Long‐Term Outcome in a Staged, Simultaneous Liver‐Kidney Transplantation of a Highly Sensitized Pediatric Patient With B and T Cell Positive Crossmatch
Background: While immunologically challenging and controversial, we report a successful case of same donor staged simultaneous liver‐kidney transplant (SLK) in a highly sensitized small child against a positive cytotoxic crossmatch (XM) and high Class I/II donor‐specific antibody (DSA) titers. Methods: Our immunologic approach included: Rituximab given prior to liver transplant (LT) and Methylprednisone and Basiliximab during the anhepatic phase. A flow XM obtained 30 min after LT was negative for T cell flow, while B cell flow remained positive, presumably related to Rituximab. The donor kidney was pumped overnight. Tacrolimus (Tac) and Cellcept (MMF) were initiated. Results: On return to the operating room 18 h later, the T cell flow XM was negative, and the B cell flow XM was weakly positive. Eculuzimab and MP were given at renal graft perfusion. Immediate urine output occurred. Normalization of liver and kidney markers was noted. At 5 years post staged SLK, there is excellent liver and kidney function and no evidence of de‐novo DSA. Interestingly, non‐HLA antibody mediated rejection of the liver only was observed 1 year post transplant. Conclusions: We present the successful staged SLK of a complex, highly sensitized child in the setting of high titers of Class I/II DSAs against positive XMs. Sophisticated immunologic management and delay of kidney transplantation by 18 h, presumably allowing the liver allograft to absorb circulating DSAs and T‐cells, resulted in excellent short and long‐term graft function.
- 1 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11) , e70514
Excellent Long‐Term Outcome in a Staged, Simultaneous Liver‐Kidney Transplantation of a Highly Sensitized Pediatric Patient With B and T Cell Positive Crossmatch
Background: While immunologically challenging and controversial, we report a successful case of same donor staged simultaneous liver‐kidney transplant (SLK) in a highly sensitized small child against a positive cytotoxic crossmatch (XM) and high Class I/II donor‐specific antibody (DSA) titers. Methods: Our immunologic approach included: Rituximab given prior to liver transplant (LT) and Methylprednisone and Basiliximab during the anhepatic phase. A flow XM obtained 30 min after LT was negative for T cell flow, while B cell flow remained positive, presumably related to Rituximab. The donor kidney was pumped overnight. Tacrolimus (Tac) and Cellcept (MMF) were initiated. Results: On return to the operating room 18 h later, the T cell flow XM was negative, and the B cell flow XM was weakly positive. Eculuzimab and MP were given at renal graft perfusion. Immediate urine output occurred. Normalization of liver and kidney markers was noted. At 5 years post staged SLK, there is excellent liver and kidney function and no evidence of de‐novo DSA. Interestingly, non‐HLA antibody mediated rejection of the liver only was observed 1 year post transplant. Conclusions: We present the successful staged SLK of a complex, highly sensitized child in the setting of high titers of Class I/II DSAs against positive XMs. Sophisticated immunologic management and delay of kidney transplantation by 18 h, presumably allowing the liver allograft to absorb circulating DSAs and T‐cells, resulted in excellent short and long‐term graft function.
- Open Access
- 21 January 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (5) , 526-535
Substitution of Glutamic Acid at Position 71 of DRβ1*04:01 and Collagen‐Specific Tolerance Without Alloreactivity
Objective: The DRB1 locus is strongly associated with both susceptibility and resistance to rheumatoid arthritis (RA). DRB1 alleles encoding the VKA or VRA epitope in positions 11, 71, and 74 confer the highest risk of developing RA, whereas the allele encoding VEA is protective. We therefore investigated the feasibility of creating antigen‐specific tolerance without inducing alloreactivity by replacing lysine with glutamic acid at position 71 in DRβ1*04:01.Methods: Individual DRB1 alleles and the DRB1*04:01K71E allele were cloned into T2 cell lines to measure binding of biotinylated peptides. Transgenic animals expressing DRB1*04:01, DRB1*01:01, or DRB1*04:01K71E were injected with collagen to measure T cell proliferation. Skin and bone marrow transplants between DRB1*04:01K71E and DRB1*04:01 mice were performed to determine if the single amino acid change at position 71 would be recognized as foreign. DRB1*04:01 mice transplanted with DRB1*04:01K71E bone marrow were injected with collagen to test if resistance to collagen sensitization could be transferred.Results: Replacing lysine (K) at position 71 in DRβ1*04:01 with glutamic acid (E) blocked collagen peptide binding and rendered the DRB1*04:01K71E mice resistant to collagen sensitization. Skin and bone marrow transplants from DRB1*04:01K71E mice were not rejected by DRB1*04:01 mice, suggesting the single E71 difference was not recognized as allogeneic. Bone marrow from DRB1*04:01K71E mice adoptively transferred antigen‐specific tolerance to collagen to DRB1*04:01 mice.Conclusion: These studies demonstrate that editing a single amino acid in DRβ1*04:01 blocks collagen peptide binding without inducing alloreactivity and could therefore represent a gene therapy approach to induce antigen‐specific passive tolerance.
- 21 January 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (5) , 526-535
Open AccessSubstitution of Glutamic Acid at Position 71 of DRβ1*04:01 and Collagen‐Specific Tolerance Without Alloreactivity
Objective: The DRB1 locus is strongly associated with both susceptibility and resistance to rheumatoid arthritis (RA). DRB1 alleles encoding the VKA or VRA epitope in positions 11, 71, and 74 confer the highest risk of developing RA, whereas the allele encoding VEA is protective. We therefore investigated the feasibility of creating antigen‐specific tolerance without inducing alloreactivity by replacing lysine with glutamic acid at position 71 in DRβ1*04:01.Methods: Individual DRB1 alleles and the DRB1*04:01K71E allele were cloned into T2 cell lines to measure binding of biotinylated peptides. Transgenic animals expressing DRB1*04:01, DRB1*01:01, or DRB1*04:01K71E were injected with collagen to measure T cell proliferation. Skin and bone marrow transplants between DRB1*04:01K71E and DRB1*04:01 mice were performed to determine if the single amino acid change at position 71 would be recognized as foreign. DRB1*04:01 mice transplanted with DRB1*04:01K71E bone marrow were injected with collagen to test if resistance to collagen sensitization could be transferred.Results: Replacing lysine (K) at position 71 in DRβ1*04:01 with glutamic acid (E) blocked collagen peptide binding and rendered the DRB1*04:01K71E mice resistant to collagen sensitization. Skin and bone marrow transplants from DRB1*04:01K71E mice were not rejected by DRB1*04:01 mice, suggesting the single E71 difference was not recognized as allogeneic. Bone marrow from DRB1*04:01K71E mice adoptively transferred antigen‐specific tolerance to collagen to DRB1*04:01 mice.Conclusion: These studies demonstrate that editing a single amino acid in DRβ1*04:01 blocks collagen peptide binding without inducing alloreactivity and could therefore represent a gene therapy approach to induce antigen‐specific passive tolerance.
- Open Access
- 30 March 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (6) , 608.e1-608.e10
Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant
- 30 March 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (6) , 608.e1-608.e10
Open AccessRevised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant
- 8 August 2022
- Published by Elsevier in Human Immunology
- Vol. 83 (10) , 730-735
HLA homozygosity is associated with Non-Hodgkin lymphoma
- 8 August 2022
- Published by Elsevier in Human Immunology
- Vol. 83 (10) , 730-735
HLA homozygosity is associated with Non-Hodgkin lymphoma
- Open Access
- 3 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (9) , 601.e1-601.e8
Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand
- 3 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (9) , 601.e1-601.e8
Open AccessLineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand
- 1 August 2016
- Published by Elsevier in Journal of Autoimmunity
- Vol. 72, 25-32
Arthritogenic peptide binding to DRB1*01 alleles correlates with susceptibility to rheumatoid arthritis
- 1 August 2016
- Published by Elsevier in Journal of Autoimmunity
- Vol. 72, 25-32
Arthritogenic peptide binding to DRB1*01 alleles correlates with susceptibility to rheumatoid arthritis
- 1 October 2015
- Published by Elsevier in Human Immunology
- Vol. 76, 22
OR11 Comparison of arthritogenic peptide binding to DRB1*01:01 and DRB1*01:02
- 1 October 2015
- Published by Elsevier in Human Immunology
- Vol. 76, 22
OR11 Comparison of arthritogenic peptide binding to DRB1*01:01 and DRB1*01:02
- 1 October 2015
- Published by Elsevier in Human Immunology
- Vol. 76, 35
OR43 Four DRβ1 amino acids mediate preferential binding of citrullinated peptides and collagen
- 1 October 2015
- Published by Elsevier in Human Immunology
- Vol. 76, 35
OR43 Four DRβ1 amino acids mediate preferential binding of citrullinated peptides and collagen